Literature DB >> 34084972

Stem cell secretome derived from human amniotic fluid affords neuroprotection in an ischemic model.

Chase Kingsbury1, Liborio Stuppia2.   

Abstract

Human amniotic fluid stem cells (hAFSCs) are growing in interest; yet, little is understood about their secretome and neuroprotective actions in different diseases, including stroke. When stem cells are grown in vitro, they release an array of cytokines and growth factors that can stimulate neuroprotective processes. Furthermore, administering secretome rather than cells may be a safer route for patients who are at risk for rejection, promoting innate restorative processes. Current literature implicates that the miRNA contents of such secretome, more specifically exosomes, may regulate the effectiveness of secretome administration. In this review, we explore what factors may promote pro-survival and pro-apoptotic pathways after the administration of hAFSCs-derived secretome in ischemic models. Copyright:
© 2021 Brain Circulation.

Entities:  

Keywords:  miRNAs; oxygen-glucose deprivation; secretome; stroke

Year:  2021        PMID: 34084972      PMCID: PMC8057106          DOI: 10.4103/bc.bc_8_21

Source DB:  PubMed          Journal:  Brain Circ        ISSN: 2394-8108


Introduction: Update on Stroke

Stroke remains a significant cause of death and chronic disability across the world. The two major subcategories of stroke are ischemic and hemorrhagic. Ischemic stroke results from occlusion of an artery that supplies blood to the brain,[1] while hemorrhagic stroke is caused by a ruptured artery or an unusual vascular design.[23] Recent data have shown that the majority of stroke incidences are ischemic in nature.[4] A disruption in the cerebral blood supply has devastating effects, such as oxidative stress, tissue damage, inflammation, and eventually death of resident neurons.[56] Currently, stroke treatment is limited to tissue plasminogen activator (tPA), which has a narrow therapeutic window.[567] Furthermore, tPA has other limitations such as cerebral ischemia/reperfusion (I/R) injury, which can cause severe disability and even mortality.[8910] Due to the unfavorable outcomes of current treatment options like I/R injury, treatments that target secondary inflammation pathways, warrant the need to be investigated.

In vitro Methods Provide Insight into Molecular Actions

In vitro mechanisms are useful in understanding the cellular and molecular actions of pathologies like stroke. Although not complete, in vitro models are critical for the translation of a treatment to a clinical setting. Furthermore, they allow for a lost-cost solution to develop in vivo models, which further improve the clinical translation. Oxygen and glucose deprivation models (OGD) are an accurate way to simulate cerebral ischemia and cell damage that occur during stroke in vitro.[111213] This model is accomplished by placing cells in a glucose-free medium while simultaneously prohibiting oxygen.[1314] Further, the OGD model undergoes reperfusion in normal oxygen conditions.[15]

Amniotic Fluid: A Source of Regenerative Properties

Current research in regenerative medicine suggests that stem cells from amniotic fluid may be promising. In adult stem cells, epigenetic changes may be preserved, thus limiting their use for specific applications.[16] However, fetal stem cells are less differentiated when collected, and could be used more broadly. Furthermore, there are limited ethical concerns since the amniotic fluid is collected during amniocentesis and cesarean section.[17] To further elucidate the therapeutic potential of amniotic fluid cells, signal transduction pathways triggered by human amniotic fluid stem cells (hAFSCs)-derived secretome in an I/R in vitro model were studied by Western blot analysis. In addition, the expression of miRNA within the exosomes of the conditioned medium was also studied. hAFSCs-derived secretome was observed to initiate pro-survival and anti-apoptotic mechanisms.[18] After microRNA analysis in the exosomes, it was found that 16 miRNAs were overexpressed and involved in the management of signaling pathways.[18] The pathways relating to I/R, including neurotrophin signaling, and those associated with neuroprotection and neuronal death, were of particular interest.[18] The evidence compiled proposes that hAFSCs-conditioned medium commences neuroprotective actions within in vitro ischemia models. These observed effects can be achieved through adjusting and initiated pro-survival processes, partially, due to the secreted miRNAs.

The Role of Secretome and Exosomes in Neuroprotection

The amniotic fluid serves as a protective liquid that surrounds the fetus providing support and critical nutrients to aid in the development of the embryo.[19] The fluid consists of main water, cells, and other chemical elements.[20] The cells are primarily fetus-derived (respiratory, epithelial, urinary, and intestinal tract), as well as connective tissues and amniotic membranes. In addition, amniotic fluid possesses other cell subtypes such as amniotic, fibroblastic, and epithelioid, differing in prevalence depending on the age of gestation.[21] Amniotic fluid mesenchymal stem cells (AFMSCs) are of particular interest given their potential for therapeutic applications. AFMSCs have shown the ability to differentiated broadly toward chondrogenic, osteogenic, and adipogenic lineages, consequently presenting as a viable candidate for regenerative and therapeutic methods.[22] However, there remains a concern on the ability of engrafted stem cells to develop into the specific cell type of the damaged area. The mechanism of action has been reported broadly,[23242526] yet some of the exogenous cells that persist into the regenerated tissue do not completely explain the regenerative effects. Potentially, the insufficient integration may be due to a degree of differentiation that took place in vitro before transplant. Furthermore, it is worth noting that only some of the cell populations may undergo differentiation. This group of cells may elicit poor immune-activating responses but may recruit nearby progenitor cells to repair the injured tissue. Several studies support this theory, highlighting the protective ability of the conditioned medium in the regeneration of damaged areas where chronic inflammation persists.[27282930] Arising from previously described theories, efforts have been targeted towards stem cells secretome, and the effects it can have on stimulating regenerative pathways in damaged areas.[313233] Within conditioned medium, there exists extracellular vesicles (EV) and other soluble factors. More recently, EV have been implicated in upregulating mesenchymal stem cells (MSCs) regenerative effects,[34353637] however, this mechanism is not fully understood. Exosomes are a subcategory of microvesicles, that have gained interests due to their ability to communicate from cell-to-cell, store biological information, serve as biomarkers, and their potential for regeneration and protection of the nervous system.[383940] Exosomes are the result of fusing with the plasma membrane and releasing its contents outside of the cell.[38] The contents of an exosome usually consist of miDNA, DNA, proteins, carbohydrates, and lipids.[4142] Since exosomes are relatively simple in structure and small in size, they can cross the blood-brain barrier and present novel approaches for treatment delivery in cerebral injuries. Therefore, exosomes provide another therapeutic route besides cell transplanatation.[43]

Mitochondria Direct Apoptosis

Deficits relating to I/R injuries can be traced back to the mitochondria. For example, when mitochondria are unable to produce a strong proton gradient, their ability to produce energy suffers and thus affect other organelles like the endoplasmic reticulum in calcium uptake. Furthermore, oxidative stress can result from changes in the mitochondria leading to a building up of reactive oxygen species.[44] As a result, irregular mitochondria often initiate pro-apoptotic factors in the cytosol or nucleus leading to apoptosis.[45]

Human Amniotic Fluid Stem Cells-Secretome Initiates Pro-Survival and Pro-Apoptotic Pathways

Following MSCs or MSCs-CM administration, a decrease in apoptosis around the injury site, upregulation of pro-inflammatory factors, enhanced axonal growth, and neurogenesis and amelioration of neurological deficits have been shown [Figure 1].[304647] Yet, it is the contents of the secretome that determine the therapeutic capacity.[48] In the CM, a myriad of regenerative properties and growth-stimulating factors exist, which originate from stem cells. Furthermore, proteomic studies demonstrate the presence of several cytokines and growth factors in CM.[4950] In fact, MSCs have an unparalleled ability to produce effective exosome-producing cells.[51]
Figure 1

A graphical abstract demonstrating the capacity of Human amniotic fluid stem cells-derived media to promote neuronal survival after exposed to ischemic conditions

A graphical abstract demonstrating the capacity of Human amniotic fluid stem cells-derived media to promote neuronal survival after exposed to ischemic conditions Given such evidence, paired with the paracrine hypothesis, which poses that stem cells elicit a positive effect by stimulating resident cells to deliver bioactive molecules and EV, the use of secretome may be more advantageous than MSCs, especially in regard to safety. Recent studies have shown that the release of the secretome from MSCs could attenuate neurological impairments observed in several neurodegenerative diseases such as traumatic brain injury, Parkinson's disease, stroke, and Alzheimer's disease.[2252535455] Conditioned media and secretome demonstrate the capacity to upregulate neurotrophins like BDNF, a vascular endothelial growth factor. Neurorestoration is initiated under the release of nerve growth factors that improve neuronal projections.[4756] Several factors support the use of hAFSCs for safe and effective treatment in stroke including highly proliferative, low tumorgenicity, immunogenicity, and anti-inflammatory activity.[57] It was found that CM and more specifically, the exosomal component served an important role in fostering cell survival.[18] Increased survival was accompanied by suppressing cell-death pathways (p75/JNK) and upregulating pro-growth pathways (BDNF/TrkB).[18] In addition, pro-survival pathways PI3K/Akt and Erk5 were increased.[18]

miRNA Contents Determines Therapeutic Capacity

Within exosomes are proteins, lipids, and regulatory RNAs that can be transferred and alter surrounding cell metabolism.[48] Interestingly, among MSC-derived exosome proteins, higher levels of mBDNF were observed. Previously, several studies demonstrated that exosomes contained various neuronal proteins, all capable of passing the blood-brain barrier.[58] Furthermore, it has been shown that high levels of mBDNF were found in both exosomal fractions and in soluble CM.[18] In addition to previously discussed exosomal contents, numerous miRNAs have been found that can initiate neurorestoration. miRNAs that have been shown to have neuroprotective effects (miR-146a-5p, miR-154-5p, miR-22-3p, miR-23a-3p, miR-27a-3p, miR-29a-3p, and miR-31-5p) were also found in the hAFSC-derived exosomes studied. In particular, miR-146a was previously demonstrated to dampen inflammation[5960] and promote new formations of oligodendrocytes[61] within the injured perinatal brain. In promoting the growth of nervous tissue, miR-154 was observed in EV derived from astrocytes.[62] In addition, miR-154 has demonstrated to seek out DKK2, causing Wnt signaling activation and β-catenin upregulation,[63] both important pathways in synaptic maintenance and neuronal survival.[64] MiR-22-3p, 23a, and 27a all have roles in inhibiting apoptosis, thus providing neuroprotection.[6566676869] Recent studies suggest that miRNAs are dynamic in their response to ischemic conditions and are present in neuroprotection, such as TNF, Hippo, and PI3K.[707172] From the miRNAs that afford neuroprotection, several genes were identified that are involved in modulating apoptosis and inflammation.[18] In the HIF-1 pathway, a systemic deactivating mechanism can be seen from the experimentally based miRNAs and target genes. However, apoptosis, neurotrophins, and PI3K-Akt pathways, all expected to be mostly inactive, were observed taking part in upregulating or downregulating various processes such as apoptosis, proliferation, and inflammation. However, this response is undeviating with the pleiotropic and adaptive nature of miRNAs, since they can regulate the expression of many genes at the epigenetic level.[73] Despite the evidence, more investigation is needed to validate the role miRNAs have in regulating neurogenic pathways following ischemic injury. Furthermore, elucidating possible molecular mechanisms will aid in explaining the protective role miRNAs play in the central nervous system. Finally, it is certainly important to study how hAFSC-derived conditioned media behaves in vivo, as there are many other cells in the central nervous system besides neurons.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  68 in total

1.  Optimal Percoll concentration facilitates flow cytometric analysis for annexin V/propidium iodine-stained ischemic brain tissues.

Authors:  Wei-Sheng Juan; Hsiao-Wen Lin; Ying-Hsin Chen; Hung-Yi Chen; Yu-Chang Hung; Shih-Huang Tai; Sheng-Yang Huang; Tsung-Ying Chen; E-Jian Lee
Journal:  Cytometry A       Date:  2012-02-06       Impact factor: 4.355

2.  Downregulation of miR-23a and miR-27a following experimental traumatic brain injury induces neuronal cell death through activation of proapoptotic Bcl-2 proteins.

Authors:  Boris Sabirzhanov; Zaorui Zhao; Bogdan A Stoica; David J Loane; Junfang Wu; Carlos Borroto; Susan G Dorsey; Alan I Faden
Journal:  J Neurosci       Date:  2014-07-23       Impact factor: 6.167

3.  Inflammation-Stimulated Mesenchymal Stromal Cell-Derived Extracellular Vesicles Attenuate Inflammation.

Authors:  Matthew T Harting; Amit K Srivastava; Siqin Zhaorigetu; Henry Bair; Karthik S Prabhakara; Naama E Toledano Furman; Jody V Vykoukal; Katherine A Ruppert; Charles S Cox; Scott D Olson
Journal:  Stem Cells       Date:  2017-11-16       Impact factor: 6.277

Review 4.  Exosomes: new molecular targets of diseases.

Authors:  Saheli Samanta; Sheeja Rajasingh; Nicholas Drosos; Zhigang Zhou; Buddhadeb Dawn; Johnson Rajasingh
Journal:  Acta Pharmacol Sin       Date:  2017-12-07       Impact factor: 6.150

5.  In vitro oxygen-glucose deprivation to study ischemic cell death.

Authors:  Carla I Tasca; Tharine Dal-Cim; Helena Cimarosti
Journal:  Methods Mol Biol       Date:  2015

6.  Drug-like delivery methods of stem cells as biologics for stroke.

Authors:  Julian P Tuazon; Vanessa Castelli; Cesar V Borlongan
Journal:  Expert Opin Drug Deliv       Date:  2019-08-05       Impact factor: 6.648

7.  MicroRNA-146a Promotes Oligodendrogenesis in Stroke.

Authors:  Xian Shuang Liu; Michael Chopp; Wan Long Pan; Xin Li Wang; Bao Yan Fan; Yi Zhang; Haifa Kassis; Rui Lan Zhang; Xiao Ming Zhang; Zheng Gang Zhang
Journal:  Mol Neurobiol       Date:  2016-01-06       Impact factor: 5.590

8.  Concentrated Conditioned Media from Adipose Tissue Derived Mesenchymal Stem Cells Mitigates Visual Deficits and Retinal Inflammation Following Mild Traumatic Brain Injury.

Authors:  Kumar Abhiram Jha; Mickey Pentecost; Raji Lenin; Lada Klaic; Sally L Elshaer; Jordy Gentry; John M Russell; Alex Beland; Anton Reiner; Veronique Jotterand; Nicolas Sohl; Rajashekhar Gangaraju
Journal:  Int J Mol Sci       Date:  2018-07-11       Impact factor: 5.923

9.  TNFα and IL-1β modify the miRNA cargo of astrocyte shed extracellular vesicles to regulate neurotrophic signaling in neurons.

Authors:  Amrita Datta Chaudhuri; Raha M Dastgheyb; Seung-Wan Yoo; Amanda Trout; C Conover Talbot; Haiping Hao; Kenneth W Witwer; Norman J Haughey
Journal:  Cell Death Dis       Date:  2018-03-05       Impact factor: 9.685

Review 10.  Paracrine Mechanisms of Mesenchymal Stromal Cells in Angiogenesis.

Authors:  Selma Maacha; Heba Sidahmed; Shana Jacob; Giusy Gentilcore; Rita Calzone; Jean-Charles Grivel; Chiara Cugno
Journal:  Stem Cells Int       Date:  2020-03-09       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.